NAPO Learns FDA to Continue Review of Crofelemer NDA
20:08 EDT 5 Sep 2012 | Businesswire
This article has expired, however you can still
download the PDF.
Preview:
Napo Pharmaceuticals, Inc. (“Napo”) was informed today that the Food and
Drug Administration (“FDA”) is continuing its review of the new drug
application (“NDA”) seeking approval of crofelemer for the treatment of
ch...
Other Sources for this Article
Napo Pharmaceuticals, Inc.
Lisa A. Conte, CEO, 415-516-2732
More From BioPortfolio on "NAPO Learns FDA to Continue Review of Crofelemer NDA"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
